Lantheus moves forward with study of 18F-flurpiridaz for MPI

05/1/2013 | AuntMinnie.com (free registration)

Lantheus Medical Imaging said the first Phase III trial involving its 18F-flurpiridaz PET agent has cleared a data analysis milestone, and the research will continue. The program comprises two trials involving 1,400 North American and European patients. The agent is being tested in myocardial perfusion imaging of patients believed or known to have coronary artery disease.

View Full Article in:

AuntMinnie.com (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Actuary
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
MetLife
Bridgewater, NJ
Vice President of Finance
Urban Health Plan, Inc.
Bronx, NY